A randomised controlled open-label clinical trial to examine the effect of six weeks treatment with tablet tolvaptan on total kidney volume when compared to no tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In addition the trial will evaluate the effects of tolvaptan on measured GFR, various safety parameters and provide material for genetic and biomarker analyses.
Researcher: